What Weight Loss to Expect: Month 1, 3, 6, and 12
Realistic GLP-1 weight-loss numbers month by month — what week 1 actually looks like, when the curve gets steepest, and where most users plateau.
Updated May 7, 2026 · 6 min read
The GLP-1 weight-loss curve is predictable in shape but variable in magnitude. People who track their progress without realistic milestones tend to either get discouraged in month one (when nothing visible has happened) or overshoot expectations in month three (when the curve is steepest). Knowing roughly where you should be at month 1, 3, 6, and 12 prevents both mistakes.
This is what the typical curve looks like at the maintenance dose of either semaglutide (2.4 mg/wk) or tirzepatide (15 mg/wk), with notes on the variance you should expect.
Month 1: appetite, not the scale
The first month is about what's happening above the neck, not what's happening on the scale.
What's typical:
- Days 3–7: Appetite suppression noticeable. "Food noise" quieter. Smaller portions feel adequate.
- Week 2: Some users see 1–3 lbs of weight loss, but a lot of that is water shift from reduced carbohydrate intake.
- Week 3–4: Real fat loss begins, but at a slow pace. Most users land between 1 and 4 lbs of total loss by the end of month 1.
What's misleading: the daily scale. Water swings of 2–4 lbs are common day-to-day, especially as eating patterns change. People who weigh themselves every morning in week 2 see noise, not signal.
What to do instead:
- Weigh once a week, same day, same conditions
- Take measurements (waist, hips, thigh) once a month — these often move before the scale does
- Take front and side photos at the start, in good lighting
The first month isn't a weight-loss month. It's a calibration month — you're learning what the drug feels like, what it does to your hunger, and how your body responds.
For more on the first-week experience, see how long semaglutide takes to work.
Month 3: the steepest part of the curve
By month 3, you've stepped up through 2–3 dose increases (depending on the molecule and your titration speed). The cumulative effect of higher doses + appetite-trained eating starts to land on the scale.
What's typical:
- Cumulative loss by month 3: 6–12 lbs for most users, or roughly 3–7% of starting body weight
- The fastest pound-per-week losses usually occur in months 2–4
- Many users describe this stretch as "I can't really overeat even if I try"
What's variable:
- Lighter starting weights (BMI 27–30) tend to see slower absolute pound losses but similar percentages
- Heavier starting weights often see dramatic absolute losses early — 15+ lbs in three months isn't unusual at BMI 40+
- Diabetic users typically lose less than non-diabetic users at the same dose
What goes wrong here: the first plateau. A meaningful number of users hit a 1–3 week stall around weeks 8–10, often coinciding with a dose-step transition. This is almost never a problem; the curve resumes once the next dose stabilizes.
For deeper coverage of stalls, see why weight loss stalls.
Month 6: the visible-change milestone
Month 6 is where most users start hearing comments from people who haven't seen them recently. Clothes fit differently. The face shape often shifts. Lab markers (A1c, lipids, blood pressure) usually move.
What's typical:
- Cumulative loss by month 6: 10–14% of starting body weight on semaglutide; 12–17% on tirzepatide
- For someone starting at 220 lbs: roughly 22–31 lbs lost on sema, 26–37 on tirz
- For someone starting at 180 lbs: roughly 18–25 lbs on sema, 22–31 on tirz
What's variable: the rate of loss starts to slow noticeably in this stretch. The first 5% comes faster than the next 5%, which comes faster than the next. By month 6, weekly losses are often 0.3–0.5% of body weight rather than the 0.7–1% common in months 2–4.
What's worth tracking now beyond the scale:
- Body composition (if you have access — DEXA, smart scale trends, even tape measurements)
- Resting heart rate — typically drops as cardiovascular load decreases
- Sleep quality — often improves dramatically by this point
- A1c if diabetic, lipid panel if dyslipidemic — many people see meaningful normalization
For more on tracking what matters, see are you losing fat or muscle? (coming soon)
Month 12: approaching the trial averages
By month 12, most users are landing within shouting distance of the published trial averages — provided they reached the full maintenance dose and stayed there.
What's typical:
- Cumulative loss by month 12: 14–18% on semaglutide at 2.4 mg, 18–22% on tirzepatide at 15 mg
- Trial averages: STEP-1 hit 14.9% at 68 weeks; SURMOUNT-1 hit 22.5% at 72 weeks
- Real-world numbers tend to land slightly below trial averages because real-world adherence and titration aren't as rigorous
What's variable: this is the stretch where the spread between high-responders and low-responders becomes most visible. The same drug at the same dose produces 8% loss in one user and 28% in another. We don't fully understand why, though gut microbiome composition, insulin sensitivity, and possibly receptor density all play roles.
What to expect after month 12:
- Months 12–18: continued slow loss, usually 1–3 additional percentage points
- Month 18+: the curve flattens dramatically. Most users settle into a new setpoint and stop losing meaningfully
This is where the question of what to do next becomes pressing. Stay on at full dose? Drop to maintenance? Stop entirely? See will I gain the weight back? for what the data actually shows about each path.
How to read your own curve
Compare yourself against the maintenance-dose typical band, not against fragmentary social-media stories. Three honest comparisons:
| Where you are | Typical range | Concerning if... |
|---|---|---|
| Month 1 | 1–4 lbs lost | Zero appetite change and zero scale movement after 4 weeks at 0.5 mg |
| Month 3 | 3–7% loss | Less than 2% loss with full adherence at therapeutic dose |
| Month 6 | 10–14% (sema) / 12–17% (tirz) | Less than 5% loss at the full maintenance dose |
| Month 12 | 14–18% (sema) / 18–22% (tirz) | Less than 8% loss with continuous full-dose use |
If you're well below the band at month 6 and you're at the full maintenance dose with good adherence, that's worth a conversation with your prescriber. Possibilities include underlying metabolic conditions, a need to switch molecules, or — sometimes — an unappreciated calorie creep that the drug isn't fully suppressing.
If you're above the band, congratulations, you're a high-responder. Your main concerns shift toward body composition, avoiding Ozempic face, and not losing weight too fast.
What's not on the curve
A few things to remember about what isn't in these numbers:
- The first 8–12 weeks of titration in the trial is rolled into the cumulative number. Real-world users often titrate slower because of side effects, which slightly delays the curve.
- Discontinuations are excluded from the trial averages. About 5–10% of users in trials stop because of side effects; their data isn't in the 14.9% figure.
- Maintenance is implicit. The trial numbers assume you reached and stayed at the maintenance dose. Real users who hold at intermediate doses (e.g., 1 mg semaglutide) typically see proportionally less loss.
The realistic summary: if you're at the maintenance dose and tracking the typical band, you're doing exactly what the drug does. The curve is what it is. Pushing past it requires more than just the drug.